Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)

NCT04401293 is registered in ClinicalTrials.gov with Northwell Health as lead sponsor.

NCT NCT04401293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04401293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)
Lead sponsor
Northwell Health
Phase
Phase 3
Overall status
Completed
Start date
April 26, 2020
Completion date
May 14, 2021
Enrollment
257 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid, sars-cov2